AC
AVTX icon

Aristides Capital’s Avalo Therapeutics AVTX Stock Holding History

Aristides Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17
Closed -$107K – 275
2021
Q3 		$107K Buy
+17
New +$138K 0.04% 144

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Aristides Capital's AVTX Position: Q4 2021 in Review

Aristides Capital sold out of Avalo Therapeutics (AVTX) in Q4 2021, closing a stake of 17 shares — an estimated $107K sold.

Aristides Capital first reported a position in AVTX in Q3 2021 and held it in 1 quarter. The position peaked at $107K in Q3 2021. 70 funds tracked by Wall St. Rank hold AVTX as of Q4 2021.

  • Aristides Capital reported no remaining Avalo Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Aristides Capital sold 17 Avalo Therapeutics shares in Q4 2021, an estimated $107K.
  • Aristides Capital first reported a position in Avalo Therapeutics in Q3 2021 and held it in 1 quarter.
  • Aristides Capital's Avalo Therapeutics position peaked at $107K in Q3 2021.
  • 70 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2021.

Based on Aristides Capital's 13F filing for Q4 2021, filed 14 Feb 2022.